282 related articles for article (PubMed ID: 15183988)
1. Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy.
Shariat SF; Menesses-Diaz A; Kim IY; Muramoto M; Wheeler TM; Slawin KM
Urology; 2004 Jun; 63(6):1191-7. PubMed ID: 15183988
[TBL] [Abstract][Full Text] [Related]
2. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer.
Kattan MW; Shariat SF; Andrews B; Zhu K; Canto E; Matsumoto K; Muramoto M; Scardino PT; Ohori M; Wheeler TM; Slawin KM
J Clin Oncol; 2003 Oct; 21(19):3573-9. PubMed ID: 12913106
[TBL] [Abstract][Full Text] [Related]
3. The expression levels and the differential expression of transforming growth factor-beta receptors in dermatofibroma and dermatofibrosarcoma protuberans.
Kubo M; Ihn H; Yamane K; Tamaki K
Br J Dermatol; 2006 May; 154(5):919-25. PubMed ID: 16634896
[TBL] [Abstract][Full Text] [Related]
4. Survivin expression is associated with features of biologically aggressive prostate carcinoma.
Shariat SF; Lotan Y; Saboorian H; Khoddami SM; Roehrborn CG; Slawin KM; Ashfaq R
Cancer; 2004 Feb; 100(4):751-7. PubMed ID: 14770431
[TBL] [Abstract][Full Text] [Related]
5. Plasma levels of transforming growth factor-1beta and alpha2-macroglobulin before and after radical prostatectomy: association to clinicopathological parameters.
Sinnreich O; Kratzsch J; Reichenbach A; Gläser C; Huse K; Birkenmeier G
Prostate; 2004 Nov; 61(3):201-8. PubMed ID: 15368477
[TBL] [Abstract][Full Text] [Related]
6. Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy.
Shariat SF; Walz J; Roehrborn CG; Montorsi F; Jeldres C; Saad F; Karakiewicz PI
J Urol; 2008 Apr; 179(4):1593-7. PubMed ID: 18295256
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor beta as a clinical biomarker for prostate cancer.
Perry KT; Anthony CT; Case T; Steiner MS
Urology; 1997 Jan; 49(1):151-5. PubMed ID: 9000208
[TBL] [Abstract][Full Text] [Related]
8. Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients.
Kim IY; Ahn HJ; Lang S; Oefelein MG; Oyasu R; Kozlowski JM; Lee C
Clin Cancer Res; 1998 Jul; 4(7):1625-30. PubMed ID: 9676836
[TBL] [Abstract][Full Text] [Related]
9. Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.
Zhang Q; Helfand BT; Jang TL; Zhu LJ; Chen L; Yang XJ; Kozlowski J; Smith N; Kundu SD; Yang G; Raji AA; Javonovic B; Pins M; Lindholm P; Guo Y; Catalona WJ; Lee C
Clin Cancer Res; 2009 May; 15(10):3557-67. PubMed ID: 19447876
[TBL] [Abstract][Full Text] [Related]
10. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.
Adler HL; McCurdy MA; Kattan MW; Timme TL; Scardino PT; Thompson TC
J Urol; 1999 Jan; 161(1):182-7. PubMed ID: 10037394
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of transforming growth factor beta 1 and nm-23 H1 antioncogene in prostate cancer: divergent correlation with clinicopathological parameters.
Stravodimos K; Constantinides C; Manousakas T; Pavlaki C; Pantazopoulos D; Giannopoulos A; Dimopoulos C
Anticancer Res; 2000; 20(5C):3823-8. PubMed ID: 11268461
[TBL] [Abstract][Full Text] [Related]
12. Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer.
Eastham JA; Truong LD; Rogers E; Kattan M; Flanders KC; Scardino PT; Thompson TC
Lab Invest; 1995 Nov; 73(5):628-35. PubMed ID: 7474936
[TBL] [Abstract][Full Text] [Related]
13. Stage-specific localization of transforming growth factor beta1 and beta3 and their receptors during spermatogenesis in men.
Zhang YQ; He XZ; Zhang JS; Wang RA; Zhou J; Xu RJ
Asian J Androl; 2004 Jun; 6(2):105-9. PubMed ID: 15154083
[TBL] [Abstract][Full Text] [Related]
14. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
[TBL] [Abstract][Full Text] [Related]
15. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy.
Shariat SF; Shalev M; Menesses-Diaz A; Kim IY; Kattan MW; Wheeler TM; Slawin KM
J Clin Oncol; 2001 Jun; 19(11):2856-64. PubMed ID: 11387358
[TBL] [Abstract][Full Text] [Related]
16. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy.
Shariat SF; Anwuri VA; Lamb DJ; Shah NV; Wheeler TM; Slawin KM
J Clin Oncol; 2004 May; 22(9):1655-63. PubMed ID: 15117988
[TBL] [Abstract][Full Text] [Related]
17. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling.
Tuxhorn JA; Ayala GE; Smith MJ; Smith VC; Dang TD; Rowley DR
Clin Cancer Res; 2002 Sep; 8(9):2912-23. PubMed ID: 12231536
[TBL] [Abstract][Full Text] [Related]
18. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
[TBL] [Abstract][Full Text] [Related]
19. Isolated seminal vesicle invasion imparts better outcomes after radical retropubic prostatectomy for clinically localized prostate cancer: prognostic stratification of pt3b disease by nodal and margin status.
Masterson TA; Pettus JA; Middleton RG; Stephenson RA
Urology; 2005 Jul; 66(1):152-5. PubMed ID: 15992904
[TBL] [Abstract][Full Text] [Related]
20. Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer.
Shariat SF; Bensalah K; Karam JA; Roehrborn CG; Gallina A; Lotan Y; Slawin KM; Karakiewicz PI
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5377-84. PubMed ID: 17875766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
